Is Becton, Dickinson and Company Stock Underperforming the S&P 500?

With a market cap of $54.8 billion, Becton, Dickinson and Company (BDX) is a global medical technology firm that develops, manufactures, and sells medical devices, laboratory equipment, and diagnostic products. BD serves healthcare institutions, researchers, laboratories, and patients worldwide.

Companies valued at $10 billion or more are generally classified as “large-cap” stocks, and BDX fits this criterion perfectly. Its operations are organized into three principal segments: BD Medical, BD Life Sciences, and BD Interventional, covering areas from medication delivery and diagnostics to surgical and interventional solutions.